Quick answer: NAD-related compounds are being studied in aging biology, but evidence in senior dogs is still limited. A randomized canine trial of a combination senolytic plus NAD+ precursor improved an owner-assessed cognition score, while objective activity measures and some other outcomes did not differ significantly. That does not prove that every NAD+ chew improves aging or cognition.
What did the randomized dog trial test?
The study enrolled dogs with mild-to-moderate cognitive impairment and compared placebo with two doses of a combined intervention containing a senolytic and NAD+ precursor.
What improved?
The owner-reported Canine Cognitive Dysfunction Rating score differed across treatment groups at the primary endpoint, with the largest improvement in the full-dose group. However, in-house cognitive testing did not show the same clear group difference.
Why combination products complicate interpretation
Because the study used both a senolytic and an NAD-related precursor, the effect cannot be assigned to “NAD+” alone or to a generic retail chew.
What should owners of senior dogs check?
- The exact compound: NAD+, NMN, NR, or another precursor.
- Amount per serving.
- Other active ingredients.
- Medication and chronic-disease context.
- Whether product claims match canine evidence.
Related PetVibess guides
- NAD+ vs. NMN vs. NR for Dogs
- NMN for Dogs: 2026 Study Explained
- NAD+ Supplements for Pets
- PetVibess NAD+ Chews
Sources
Written by the PetVibess Editorial Team. General educational information only; not treatment or dosing advice. Updated October 11, 2026.